BioInformant

Your Global Leader in Stem Cell Market Research

Home » bioinformant

L2 Bio, LLC Launches C-ROW Site Beta: A Breakthrough Research Project in Costa Rica Targeting Osteoarthritis

By Leave a Comment

Innovative Participant-Funded Study Harnesses Enhanced Autologous Adipose-Derived Stem Cells to Combat Degenerative Joint Disease

ESCAZU, COSTA RICA, June 1,  2026 — L2 Bio, LLC has formally announced the launch of the C-ROW Site Beta (C-ROW), an innovative, participant-funded research project based in Costa Rica welcoming the safety and convenience of utilizing local participation of your USA or Canadian based doctor. The study centers on the use of enhanced autologous adipose-derived stem cells (ADSCs) to address the debilitating progression of osteoarthritis. [Read more…]

Pluristyx and Qkine Announce a Reciprocal Distribution Agreement in Support of Optimized Growth Factor Differentiation of Induced Pluripotent Stem Cell (iPSC)

By Leave a Comment

SEATTLE, WA and CAMBRIDGE, UK — Pluristyx, a leading provider of clinical-grade induced pluripotent stem cell (iPSC) solutions, and Qkine, a pioneer in the manufacture of high-purity, animal-free growth factors and cytokines, today announced a distribution agreement to support streamlined and efficient R&D and manufacturing of differentiated cells and tissues from iPSC. This collaboration will provide researchers, product manufacturers, and therapeutic developers with a streamlined, high-performance workflow, pre-qualified to deliver reliable differentiation of iPSCs into product cells and tissues. [Read more…]

Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges

By Leave a Comment

Backed by a €12M Bpifrance grant, the program builds a GMP-compatible manufacturing platform for iPSC-derived cell therapies — directly applicable to biotech and pharma iPSC programs.

Toulouse, 2026 April 16th  – Scale-up remains one of the most critical unsolved challenges in iPSC-derived cell therapy. Despite strong clinical promise, most manufacturing processes today can only supply material for a very limited number of patients — a bottleneck that limits clinical progression and commercial viability across the field. [Read more…]

RoosterBio and MineBio Life Sciences Partner to Expand Access to Scalable, High Quality MSC and Exosome Bioprocessing Solutions in China

By Leave a Comment

Partnership Delivers RoosterBio’s Research-Grade and CliniControlTM cGMP Media Platforms to China’s Leading Cell and Gene Therapy Developers; MineBio Holds Import Approval for Immediate Order Fulfillment

FREDERICK, MD., April 8, 2026 — RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered bioprocess media, and advanced therapy manufacturing solutions for hMSCs and exosomes, today announced an exclusive distributor partnership with MineBio Life Sciences Limited (MineBio), a trusted partner to China’s biopharmaceutical and advanced therapy community. Under the agreement, MineBio will distribute RoosterBio’s full platform of research-grade and CliniControlTM cGMP-grade MSC and exosome bioprocessing media throughout China. Critically, MineBio has already secured import approval for RoosterBio’s research use only and cGMP CliniControlTM MSC and exosome bioprocessing media platform, enabling orders to be fulfilled without delay. [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0